Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antenatal Steroids for Preterm Birth is Cost Effective

Publish date:: March 11, 2019

Key clinical point: Antenatal betamethasone cost-effectively improved infant outcomes among pregnant women at high risk for preterm birth.

Major finding: Antenatal betamethasone treatment was linked to $4,681 per mother-infant pair, compared with $5,379 without corticosteroids (P = .02 for $698 difference).

Study details: The findings are based on a secondary analysis of a randomized clinical trial from October 2010 to February 2015 involving 2,821 mothers at high risk for preterm birth, and their infants.

Disclosures: The National Institutes of Health funded the research. Dr. Gyamfi-Bannerman received a grant from AMAG pharmaceuticals during the conduct of the study.

Citation:

Gyamfi-Bannerman C. JAMA Pediatr. 2019 Mar 11. doi: 10.1001/jamapediatrics.2019.0032.

This Week's Must Reads

Annual WCC visits significantly limit asthma worsening,

Does daily inhaler monitoring improve asthma outcomes in children?,

More severe AD correlates with worse sleep health and attention problems in children,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Shortcomings identified in study of acne videos on TikTok,

Must Reads in Business of Medicine

Chinese American families suffer discrimination related to COVID-19,

Quality improvement program expands early childhood screening,

Educational intervention curbs use of antibiotics for respiratory infections,

Men occupy most leadership roles in medicine,

Gender pronouns in EMR preferred by many gender nonconforming teens,